How AI is Reshaping Compliance and Quality Management in the Life Sciences Sector in 2025
Doron Sitbon, Founder & CEO at Dot Compliance.
As AI and digital health solutions transform the life sciences, organisations are faced with a new challenge: bridging the "last-mile problem" to translate AI’s potential into real-world business use cases. Dot Compliance’s Founder and CEO, Doron Sitbon, proposes a shift from reactive to proactive, predictive quality management, where AI can identify potential issues before they occur. Sitbon shares how this transformation reshapes the role of quality professionals into data-driven decision-makers and the future of intelligent, multi-stage compliance processes.
1. How is AI transforming compliance and quality management in the life sciences sector today?
AI is shifting the role of quality professionals from messengers to data-driven decision-makers. Traditionally, compliance relied on manual processes, but AI is now acting as a digital assistant by sifting through vast amounts of data, identifying trends, and predicting potential issues before they occur. This allows professionals to transition from managing paperwork to analyzing insights and making strategic decisions. AI-driven solutions provide intuitive visualization tools, helping organizations quickly identify outliers, correlations, and areas for improvement. AI is also driving a broader cultural shift toward data maximization, where companies recognize the long-term value of collecting and repurposing data to enhance compliance and quality processes.
2. What are the biggest challenges companies face when integrating AI into compliance and quality processes, and how can they overcome them?
One of the biggest challenges in integrating AI into compliance and quality processes is bridging the "last-mile problem"—effectively mobilizing AI’s capabilities into real-world business use cases. While AI has immense potential, organizations must align its capabilities with specific industry needs and economic value. This requires deep expertise in both data science and life sciences, along with strong change management to drive adoption. Risk management is also critical, ensuring AI solutions are reliable and aligned with regulatory requirements. Companies must establish effective governance frameworks, calibrate AI outputs, and track incidents related to AI usage to mitigate risks and build trust in AI-driven compliance processes.
3. How can AI help pharmaceutical companies maintain regulatory adherence while streamlining compliance workflows?
AI has the capability to analyze vast amounts of data relevant to specific compliance workflows and make that information available to the people who need to make decisions. The first element is gathering and organizing data to support each stage of the workflow. Automation can also play a role in compliance workflows, helping with tasks like collecting feedback from different parties and sending reminders to ensure responses are provided on time. Additionally, AI-driven processes can streamline workflows by nudging compliance owners to obtain necessary feedback efficiently. On the analytical side, AI can generate insights through trend analysis, abnormality detection, and continuous monitoring of key compliance aspects, helping companies stay ahead of potential issues.
4. What role does AI play in identifying and mitigating compliance risks before they escalate into regulatory violations?
AI is shifting from single-stage tasks to multi-stage, process-driven decision-making, which has significant implications for compliance risk management. Intelligent AI agents can take on specific compliance missions, translating them into a series of AI-driven actions that proactively identify risks before they escalate. When AI extends beyond digital workflows into the physical world—such as pharmaceutical manufacturing and care delivery—compliance risks will become more complex. Ensuring regulatory alignment in this new landscape will require AI-driven monitoring systems and reflection agents that provide oversight, flag potential issues, and introduce human review where needed.
5. How can AI improve the accuracy and efficiency of quality control processes in pharmaceutical manufacturing?
Today’s pharmaceutical manufacturing shop floors generate an exponential number of data points throughout the process. AI can analyze these data points, synchronizing information from different sources—such as sensor readings from one section—and determining how they relate to additional data elsewhere. So AI could really take statistical process control (SPC) to the next level by identifying gold standards that the specific manufacturing process should follow, detecting deviations from required specifications early, and eventually, automating human tasks on the production line. I think that the next generation of robots will be capable of handling more of these activities, particularly in sterile, aseptic environments, where their use can help minimize contamination risks.
6. With AI being increasingly used for compliance reporting and regulatory submissions, how can companies ensure the integrity and reliability of AI-generated documentation?
For each specific business use case, companies need to establish guardrails that provide clear indicators of data quality, integrity, and reliability. While AI has significant potential to streamline compliance reporting and regulatory submissions, human supervision remains essential to ensure accuracy and reliability in AI-generated documentation.
7. Many life sciences companies rely on legacy compliance systems. How can AI be integrated with these systems without causing disruption?
Technically, AI could be integrated into legacy compliance systems; however, this is a missed opportunity to re-engineer your processes and gain the true value of AI.
To truly leverage the capabilities of AI, you need to redesign your processes to be agentic driven, meaning that some of the activities that are now done through manual data entry into a legacy system should be converted into an agentic process that would streamline the process.
8. How can AI-driven predictive analytics help pharmaceutical firms proactively manage quality and compliance risks?
AI-driven predictive analytics enables pharmaceutical organizations to identify risks, predict deviations, and take proactive action before quality and compliance issues escalate. By analyzing eQMS and production data, AI detects patterns that signal potential failures, reducing noncompliance, recalls, and regulatory penalties. It enhances CAPA management, prioritizes complaints based on risk, and strengthens supplier quality oversight by predicting material or process failures. AI also helps organizations stay ahead of evolving regulations by automating compliance monitoring, ensuring faster, data-driven decision-making. This shift from reactive to proactive quality management improves efficiency, reduces costs, and helps meet compliance.
9. With increasing concerns around AI decision-making transparency, how can companies ensure regulatory bodies trust AI-driven compliance processes?
AI governance will become a major focus in 2025 as regulations evolve. Right now, AI regulation is in its “wild west” phase, but emerging frameworks like the EU AI Act will introduce stricter compliance requirements. Companies must prepare for increased scrutiny over algorithm accuracy, bias, and fairness. Perhaps in the future when organizations implement an AI solution, they will also implement a reflection agent—AI models that monitor and evaluate other AI systems. These types of agents could provide oversight, helping to identify errors and ensure compliance. However,, human-in-the-loop mechanisms will remain essential, allowing experts to review AI-driven decisions and make necessary adjustments to maintain accountability.
10. What cybersecurity and data integrity challenges arise when implementing AI in compliance and quality management, and how should they be addressed?
It’s important to have trust in your data; however, data can be misleading. To prevent this, organizations need to understand and implement the necessary data governance processes that will help ensure data integrity and security and ensure AI decisions are free from bias.
Risk management is also essential to ensuring accuracy, reliability, and alignment with business needs. This involves calibrating AI outputs and tracking incidents related to AI usage, which require strong cybersecurity measures and protection against AI-related liabilities.
11. Looking ahead, what are the most significant AI-driven trends shaping the future of compliance and quality management in the life sciences sector?
In 2025, I see AI in life sciences moving from early adoption to a stage where more organizations have found effective ways to use AI. The focus will shift to addressing the "last mile problem"—delivering AI's value directly to the point of consumption or creation. This requires bridging the gap between AI’s potential and its practical use, combining deep expertise in data science with industry-specific knowledge, and deploying it thoughtfully. The basic principle of medicine, “do no harm” comes in here. Organizations must adopt the same principle to deploy AI and ensure that the change management, safeguards and risk management are done the right way.
Additionally, most of the AI processes we’re going to see emerging in 2025 will be much more agent process-oriented. AI will shift to multistage processes driven by intelligent agents, resulting in greater complexity. To succeed, business leaders must cultivate a data-driven culture, scale capabilities, train teams, and ensure decisions are guided by accurate, analyzed data.
Author Bio
Doron Sitbon is the Founder and CEO at Dot Compliance, the leading provider of AI-powered electronic quality management and compliance solutions for the life sciences industry. Doron is a dynamic and highly accomplished entrepreneur with over two decades of global executive leadership experience in the enterprise SaaS solution industry.
